IRD Q2 2023 Earnings — Opus Genetics, Inc. Revenue & Financial Results | Market Cap Arena

IRDOpus Genetics, Inc.

$349M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M

Gross Profit

$4M100.0% margin

Operating Income

-$5M-146.7% margin

Net Income

-$5M-135.0% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+110.1%

Cash Flow

Operating Cash Flow

$989,000

Free Cash Flow

$989,000

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$43M

Total Liabilities

$6M

Stockholders' Equity

$38M

Cash & Equivalents

$40M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$0	—
Gross Profit	$4M	$0	—
Operating Income	-$5M	-$5M	-9.1%
Net Income	-$5M	-$5M	-0.7%